(redirected from HBeAg)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia.
Related to HBeAg: anti-HBe, HBeAb, HBcAg
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to antigen

any substance (as a toxin or enzyme) that stimulates an immune response in the body (especially the production of antibodies)

References in periodicals archive ?
Sonuc olarak, kilavuzlarda her ne kadar HBeAg serokonversiyonundan sonra NA kesilmesi onerilse de hastalarin onemli kisminda nuks gelismektedir.
Inhibitory efficiency of antiviral agents was assessed only with HBeAg. NCC dose-dependently inhibited HBeAg production by HepG2.2.15 cells and HepG2.RL1 cells (Fig.
Based on literature data, the general recommendation with regard to treatment duration is to continue oral antiviral therapy for at least 6 months after HBeAg seroconversion.
Thirdly, a G to T transversion at position 1862 in the precore region occurs frequently in subgenotype A1, and is more common in HBeAgnegative than in HBeAg-positive South African carriers, [28,38] which affects HBeAg expression at the post-translational level.
The levels of HBsAg, anti-HBs, HBeAg, and anti-HBe were measured using an Abbott Architect i2000 detection reagent (Abbott Diagnostics, Abbott Park, IL, USA); the HBsAg dynamic range was 0.05-250.00 U/ml.
A pre-core mutant of HBV does not produce HBeAg, resulting in HBeAg-negative CHB.
Both HBeAg status and serum HBV viral load were not significantly different among patients with different stages of liver fibrosis.
Despite its prevalence, there is a paucity of data regarding on HBeAg status among pregnant women which helps to understand the frequency of highly infective HBV carriers in the given region which in turn helps to design and implement preventive and control measures and awareness of transmission route of HBV infection.
The quantitative values of the following indices were tested by Elecsys (Roche Diagnostics GmbH, Mannheim, Germany) at the noted reference ranges: HBsAb, 0 - 10 IU/L; HBeAg, <1.0 cut-off index (COI); HBeAb, >1.0 COI; and HBcAb, >1.0 COI.
Inclusion criteria of patients were age [greater than or equal to] 18 years; HBsAg, HBeAg, and HBV DNA positive for more than 6 months; serum ALT of <2x ULN; and signed informed consent for liver biopsy.
Additional markers, including HBV "e" protein (HBeAg) and HBV DNA, indicate levels of viral replication in the liver.
The amount of HBsAg and HBeAg in the supernatant was determined using ELISA kits (Shanghai KeHua Biotech, China) according to the manufacturer's protocol.
We obtained patients' age and sex and assessed platelet count, cirrhosis status, HBV e antigen (HBeAg) and HB e antibody (anti-HBe) status, HBV genotype, HBV DNA level, basal core promoter mutations, and precore stop codon mutations.
Objective: To determine the frequency of HBeAg positivity in chronic hepatitis B infected patients.
Persistent HBV infection, especially following HBeAg seroconversion, is a highly dynamic disease with significant fluctuations of HBV-DNA which may be observed in every phase of disease [1].